

Claims

- 5 1. A suppository containing a composition, essentially consisting of meloxicam or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, characterized in that at least one of the excipients is a polyalkylenglycol.
- 10 2. A suppository capsule according to claim 1, characterized in that the suppository is a soft gelatine capsule suitable for rectal administration.
3. A suppository capsule according to claim 1 or 2, characterized in that the composition comprises the meloxicam meglumin salt.
- 15 4. A suppository capsule according to claim 1 or 2, characterized in that the composition comprises the free meloxicam base.
- 20 5. A suppository according to claim 1 to 4, characterized in that the polyalkylenglycol is selected from the group consisting of polyethylenglycol 400, polyethylenglycol 4000 and polyethylenglycol 6000.
- 25 6. A suppository according to claim 1 to 5 characterized in that it contains 0.1 % by weight or more of a solubilizer or a mixture of solubilizers of the overall weight of said composition.
7. A suppository according to claim 1 to 6 characterized in that the composition contains 1 to 20  $\mu\text{g}$  of the free meloxicam base per mg of the composition.
- 30 8. A suppository according to claim 1 to 7 characterized in that the composition contains at least 0.2 mg of the solubilizer or mixture of solubilizers per mg of the free meloxicam base.

9. A suppository according to claim 1 to 8 which contains a composition consisting of
- a) 1 to 20 mg of meloxicam,
  - b) 500 to 1500 mg of a one or more polyalkylenglycols selected from the group consisting of polyethylenglycol 400, polyethylenglycol 4000 and polyethylenglycol 6000, and optionally
  - c) one or two additional excipients.
10. A method for preparation of a suppository according to claim 1 to 9, which comprises the steps of
- a) intimately mixing of meloxicam or a pharmaceutically acceptable salt thereof with the melted solubilizer, and
  - b) encapsulating or molding of the composition obtained in step a) by a conventional method.
11. Use of a suppository according to claim 1 to 9 for the preparation of a medicament with enhanced bioavailability for the treatment or prevention of polyarthritis, rheumatoid arthritis or inflammation diseases.